FDA drug approval reform could produce substantial economic gains, according to a new Unleash Prosperity report that presents a $10 trillion estimate of cumulative value if approval timelines are shortened. The paper — titled “The Multi-Trillion Dollar Opportunity in Reforming the FDA” — models how cutting review time could speed access to therapies, encourage investment and increase competition; those dollar and timing figures are presented as estimates, not guarantees.
“It takes about a decade from start to finish to come through FDA,” Tomas Philipson, a lead author, told Fox Business. “Most of that time is not spent on safety. Most of the time is spent on effectiveness trials.”
Report authors and economist Tomas Philipson discuss FDA timelines.
FDA drug approval reform: report summary
The Unleash Prosperity report argues that modest changes to how the Food and Drug Administration evaluates effectiveness could accelerate approvals by one to six years in many cases; the range and pace of acceleration are estimates based on the report’s modeling assumptions. The paper quantifies potential economic gains and presents a “more than $10 trillion” estimate as the aggregate value of faster innovation, earlier patient uptake and stronger incentives for research and development over a multi-decade horizon (this $10 trillion amount is an estimate, not a guaranteed outcome), according to the report and Fox Business coverage of the paper.
Those projections depend on multiple assumptions: how much faster new products would reach market, how quickly clinicians and insurers would adopt them, and how investment flows would change. The report frames its headline numbers as modeled scenarios to illustrate possible scale rather than exact forecasts, per the authors’ framing in the report and Philipson’s remarks to Fox Business.
Why approvals take so long
The report and Philipson emphasize that the FDA timeline combines many phases: preclinical work, multiple stages of clinical trials, and formal regulatory review. They argue that the portion of time devoted to demonstrating effectiveness in larger randomized trials — not initial safety checks — represents a major share of the total development calendar. Philipson described this as a structural feature that, if addressed, could materially shorten approval timelines, as he told Fox Business.
That view is presented in the report as an interpretation supported by analysis; it is not offered as definitive proof that safety assessments are negligible. The report and media coverage make plain that safety testing, manufacturing standards and post-market surveillance remain essential components of a product’s life cycle and could limit how quickly regulators should move.
Proposed fixes and tradeoffs
Unleash Prosperity outlines several reforms intended to reduce time spent on effectiveness evaluations while aiming to keep safety protections in place. Recommended changes include broader use of artificial intelligence to analyze trial data and detect signals more quickly, adoption of adaptive or streamlined clinical-trial designs that can reach conclusions faster, and expanded access pathways such as right-to-try programs for certain patients. The report presents expected timing reductions (for example, cutting roughly a year in some cases) as estimates tied to particular reforms and adoption rates.
Each option involves tradeoffs the report notes. AI tools can speed data processing but require validation to avoid bias and ensure transparency. Adaptive trials may reach endpoints sooner but can leave greater uncertainty about long-term effectiveness or rare adverse events. Expanded pre-approval access can help seriously ill patients but complicates the evidence base for regulators and payers. The report and Fox Business coverage qualify these ideas as proposals with benefits and risks rather than unalloyed solutions.
Global competition and investment risk
The report warns that a faster, lower-cost clinical-trial environment in other countries — often highlighted with reference to China — could attract development activity and investment away from the United States. That strategic risk is framed as a reason for U.S. policymakers to consider reforms: if approval timelines remain comparatively long, manufacturers and funders might favor jurisdictions with quicker paths to large markets. The report treats the likelihood and scale of such shifts as estimates that depend on policy choices and industry responses, according to the paper and its media coverage in Fox Business.
Shifts in trial location can also affect data standards, participant diversity and supply chains, meaning competition-driven changes have complex downstream effects that the report flags as additional considerations.
Potential impact on patients and costs
A central mechanism in the report is that faster approvals would accelerate patient access to effective therapies and could, by increasing the number of entrants and reducing exclusive monopoly windows, place downward pressure on prescription drug prices. The report’s estimates of economic gain and timing reductions underpin this channel, but the authors and Fox Business emphasize that these links are model-based estimates that depend on market structure, payer behavior and manufacturing capacity.
Faster market entry can shorten the period when a single product faces little competition, potentially lowering prices over time. However, real-world effects on costs depend on insurance design, rebate systems, supply constraints and policy choices on pricing and reimbursement. The report’s $10 trillion figure, again, is an estimate contingent on how these forces play out.
Policymakers weighing reform must balance potential gains against uncertainty: speeding approvals could bring earlier benefits to patients but may increase the need for robust post-market surveillance and clear data standards to detect and manage safety risks as evidence grows after approval.
Graphical view of drug trial activity and global competition.
In short, the reforms outlined are framed by the authors as possible ways to speed drugs to patients and encourage investment; the economic and timing outcomes in the report are presented as estimates and depend on many contingent factors.
Source attribution
This article draws on reporting by Fox Business and the Unleash Prosperity paper titled “The Multi-Trillion Dollar Opportunity in Reforming the FDA.” Full Fox Business coverage of the report is available at https://www.foxbusiness.com/politics/economist-says-one-fda-fix-could-save-lives-add-10-trillion-economy. Tomas Philipson, a lead author, is quoted in the Fox Business article and is identified in the Unleash Prosperity report. The $10 trillion and timing figures in this story are estimates as presented in the report and coverage.
